1. Home
  2. CMCL vs CABA Comparison

CMCL vs CABA Comparison

Compare CMCL & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caledonia Mining Corporation Plc

CMCL

Caledonia Mining Corporation Plc

HOLD

Current Price

$19.62

Market Cap

396.3M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.96

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCL
CABA
Founded
1992
2017
Country
Jersey
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.3M
319.6M
IPO Year
2003
2019

Fundamental Metrics

Financial Performance
Metric
CMCL
CABA
Price
$19.62
$2.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$28.00
$14.50
AVG Volume (30 Days)
237.7K
4.1M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.54
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$1.26
52 Week High
$38.75
$4.23

Technical Indicators

Market Signals
Indicator
CMCL
CABA
Relative Strength Index (RSI) 39.50 40.86
Support Level $18.45 $2.74
Resistance Level $21.80 $3.34
Average True Range (ATR) 0.86 0.21
MACD 0.02 -0.01
Stochastic Oscillator 35.67 31.97

Price Performance

Historical Comparison
CMCL
CABA

About CMCL Caledonia Mining Corporation Plc

Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: